Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections.
Clin Infect Dis
; 68(Suppl 3): S200-S205, 2019 04 08.
Article
em En
| MEDLINE
| ID: mdl-30957168
Bacterial skin infections result in significant morbidity and have contributed to enhanced health-care resource utilization. The problem is heightened by emerging antimicrobial resistance. Multiple novel agents active against resistant pathogens that cause skin infections-including dalbavancin, tedizolid phosphate, oritavancin, and delafloxacin-have been approved over the past 5 years. Common features of these agents include gram-positive activity and favorable safety. Of these agents, delafloxacin is unique in being active against both gram-positive and gram-negative pathogens that cause skin infections, including those resistant to other antimicrobial agents. It is, therefore, an effective option for the treatment of skin infections.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Métodos Terapêuticos e Terapias MTCI:
Plantas_medicinales
Assunto principal:
Testes de Sensibilidade Microbiana
/
Antibacterianos
Idioma:
En
Revista:
Clin Infect Dis
Ano de publicação:
2019
Tipo de documento:
Article